Literature DB >> 33855586

Which ultrasound image plane is appropriate for evaluating the taller-than-wide sign in the risk stratification of thyroid nodules?

Suh Young Kim1, Dong Gyu Na2, Wooyul Paik1.   

Abstract

OBJECTIVES: This study aimed to determine the ultrasound (US) image plane appropriate for evaluating the taller-than-wide (TTW) sign in the risk stratification of thyroid nodules using the five widely used risk stratification systems (RSSs).
METHODS: A total of 1905 consecutive thyroid nodules with final diagnoses were included. The TTW sign was prospectively assessed in the transverse and longitudinal US image planes. The diagnostic performances of the TTW sign and biopsy criteria by the RSSs for malignancy were compared by sensitivity, specificity, and receiver operating characteristic curve analysis between the two criteria of TTW signs according to image planes (criterion 1, transverse plane; criterion 2, either transverse or longitudinal plane).
RESULTS: Of all 1905 nodules, 1481 (77.7%) were benign and 424 (22.3%) were malignant. The criteria 1 and 2 of TTW signs had similar sensitivities (37.5% and 38.7%) and specificities (94.8% and 94.4%) with minimal differences, and the area under the curve (AUC) of TTW signs for malignancy was not significantly different between criteria 1 and 2 (0.662 and 0.665, p = 0.158, respectively). The sensitivity, specificity, and AUC of biopsy criteria by the five RSSs were not significantly different between criteria 1 and 2 in nodules ≥ 1 cm (p ≥ 0.157, p ≥ 0.317, and p ≥ 0.198, respectively).
CONCLUSIONS: The diagnostic performances of the TTW sign and biopsy criteria of the five RSSs were similar between criteria 1 and 2. TTW signs by criterion 1 (transverse plane) may be appropriate in the risk stratification of thyroid nodules. KEY POINTS: • The diagnostic performance of the taller-than-wide sign by ROC analysis was not significantly different between US image plane criteria (transverse plane vs. either transverse or longitudinal plane). • The diagnostic performances of biopsy criteria for malignancy by the five risk stratification systems were similar between the two taller-than-wide sign criteria. • The taller-than-wide sign using the transverse plane may be appropriate in the risk stratification of thyroid nodules.

Entities:  

Keywords:  Biopsy; Thyroid neoplasms; Thyroid nodule; Ultrasonography

Year:  2021        PMID: 33855586     DOI: 10.1007/s00330-021-07936-4

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  3 in total

1.  Introducing a Pole Concept for Nodule Growth in the Thyroid Gland: Taller-than-Wide Shape, Frequency, Location and Risk of Malignancy of Thyroid Nodules in an Area with Iodine Deficiency.

Authors:  Manuela Petersen; Simone A Schenke; Michael Zimny; Rainer Görges; Michael Grunert; Daniel Groener; Philipp Seifert; Peter E Stömmer; Michael C Kreissl; Alexander R Stahl
Journal:  J Clin Med       Date:  2022-05-01       Impact factor: 4.964

Review 2.  2021 Korean Thyroid Imaging Reporting and Data System and Imaging-Based Management of Thyroid Nodules: Korean Society of Thyroid Radiology Consensus Statement and Recommendations.

Authors:  Eun Ju Ha; Sae Rom Chung; Dong Gyu Na; Hye Shin Ahn; Jin Chung; Ji Ye Lee; Jeong Seon Park; Roh-Eul Yoo; Jung Hwan Baek; Sun Mi Baek; Seong Whi Cho; Yoon Jung Choi; Soo Yeon Hahn; So Lyung Jung; Ji-Hoon Kim; Seul Kee Kim; Soo Jin Kim; Chang Yoon Lee; Ho Kyu Lee; Jeong Hyun Lee; Young Hen Lee; Hyun Kyung Lim; Jung Hee Shin; Jung Suk Sim; Jin Young Sung; Jung Hyun Yoon; Miyoung Choi
Journal:  Korean J Radiol       Date:  2021-10-26       Impact factor: 3.500

3.  Development and validation of a novel diagnostic tool for predicting the malignancy probability of thyroid nodules: A retrospective study based on clinical, B-mode, color doppler and elastographic ultrasonographic characteristics.

Authors:  Shangyan Xu; Xiaofeng Ni; Wei Zhou; Weiwei Zhan; Huan Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-20       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.